Cell-free DNA screening
for trisomy 13, 18 and 21

Cell‐free DNA screening for trisomy 13,18 and 21

 

Cell‐free DNA screening for trisomy 13,18 and 21 consists in the analysis of DNA fragments from the fetus(es), those DNA fragments being present in the maternal blood during pregnancy. Although it is a genetic test, the aim is not to analyze the genome of the fetus, but only to evaluate the relative proportion of each of the chromosomes 13, 18 and 21 in order to detect an excess of 13, 18 or 21 genetic material when the fetus carries a trisomy 13, 18 or 21. In practice, this over-representation is tiny, considering that the fetal DNA represents only 10% of the DNA present in the maternal blood. This test thus requires a powerful analysis method, the Next Generation Sequencing (NGS) combined with a high performance...

Learn more

Agenda

Scientific evening

November 2018
M T W T F S S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30

News

11
09
2016

More than 25 000 tests

To date, more than 25 000 pregnant women received a Cell‐free DNA screening for trisomy 13,18 and 21 performed...

Read more
04
07
2016

More than 9.600 tests

To date, more than 9.600 pregnant women from entire France received a Cell‐free DNA screening for trisomy...

Read more
02
04
2016

Cerba will make a presentation in 8èmes Assises de Génétique Humaine

Jean Marc, Medical Biologist at Cerba Laboratory, will make a presentation during the next « 8eme...

Read more